Pekin Hardy Strauss’s ClearPoint Neuro CLPT Stock Holding History

Pekin Hardy Strauss’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Buy	143,375 +3,000	+2%	+$37.5K	0.23%	117
2026 Q1	$1.28M	Buy	+140,375	New	+$1.77M	0.13%	181
2025 Q3	–	Sell	-50,575	Closed	-$604K	–	413
2025 Q2	$604K	Buy	50,575 +1,750	+4%	+$22K	0.07%	223
2025 Q1	$581K	Buy	48,825 +575	+1%	+$8.94K	0.07%	229
2024 Q4	$742K	Hold	48,250	–	–	0.09%	197
2024 Q3	$541K	Buy	+48,250	New	+$462K	0.07%	230

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Pekin Hardy Strauss's CLPT Position: Q2 2026 in Review

Pekin Hardy Strauss increased its ClearPoint Neuro (CLPT) stake by 2.1% in Q2 2026, buying an estimated $37.5K and bringing the position to 143,375 shares worth $2.56M. The position accounts for 0.23% of the portfolio, ranked #117.

Pekin Hardy Strauss first reported a position in CLPT in Q3 2024 and has held it in 6 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Pekin Hardy Strauss held 143,375 shares of ClearPoint Neuro worth $2.56M as of Q2 2026.
Pekin Hardy Strauss bought 3,000 ClearPoint Neuro shares in Q2 2026, an estimated $37.5K.
ClearPoint Neuro made up 0.23% of Pekin Hardy Strauss's portfolio in Q2 2026, its #117 holding.
Pekin Hardy Strauss first reported a position in ClearPoint Neuro in Q3 2024 and has held it in 6 quarters since.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.